The U.S. Food and Drug Administration late last year got more leverage over pharmaceutical companies that received accelerated approvals for their drugs. How will the agency use its new powers?
The U.S. Food and Drug Administration late last year got more leverage over pharmaceutical companies that received accelerated approvals for their drugs. How will the agency use its new powers?